Design, synthesis, and preclinical evaluations of novel 4-substituted 1,5-diarylanilines as potent HIV-1 non-nucleoside reverse transcriptase inhibitor (NNRTI) drug candidates.
about
A comparison of the ability of rilpivirine (TMC278) and selected analogues to inhibit clinically relevant HIV-1 reverse transcriptase mutantsExtension into the entrance channel of HIV-1 reverse transcriptase—Crystallography and enhanced solubilityOptimization of the antiviral potency and lipophilicity of halogenated 2,6-diarylpyridinamines as a novel class of HIV-1 NNRTIS.Physicochemical property-driven optimization of diarylaniline compounds as potent HIV-1 non-nucleoside reverse transcriptase inhibitors.Optimization of N-aryl-6-methoxy-1,2,3,4-tetrahydroquinolines as tubulin polymerization inhibitorsInvestigational reverse transcriptase inhibitors for the treatment of HIV.Synthesis, biological evaluation, and physicochemical property assessment of 4-substituted 2-phenylaminoquinazolines as Mer tyrosine kinase inhibitorsN-aryl-6-methoxy-1,2,3,4-tetrahydroquinolines: a novel class of antitumor agents targeting the colchicine site on tubulin.Novel HIV-1 Non-nucleoside Reverse Transcriptase Inhibitor Agents: Optimization of Diarylanilines with High Potency against Wild-Type and Rilpivirine-Resistant E138K Mutant VirusOptimization of 4-(N-cycloamino)phenylquinazolines as a novel class of tubulin-polymerization inhibitors targeting the colchicine site.Novel HIV-1 non-nucleoside reverse transcriptase inhibitors: a patent review (2011-2014).Novel diarylpyrimidines and diaryltriazines as potent HIV-1 NNRTIs with dramatically improved solubility: a patent evaluation of US20140378443A1.Identification of Better Pharmacokinetic Benzothiazinone Derivatives as New Antitubercular Agents.Design, synthesis, and biological evaluation of novel trifluoromethyl indoles as potent HIV-1 NNRTIs with an improved drug resistance profile.Drug-like property-driven optimization of 4-substituted 1,5-diarylanilines as potent HIV-1 non-nucleoside reverse transcriptase inhibitors against rilpivirine-resistant mutant virus.Synthesis and Preliminary Antiviral Activities of Piperidine-substituted Purines against HIV and Influenza A/H1N1 Infections.Design and synthesis of tetrahydrophthalimide derivatives as inhibitors of HIV-1 reverse transcriptase.Synthesis and SARs of indole-based α-amino acids as potent HIV-1 non-nucleoside reverse transcriptase inhibitors.Diaryl ethers with carboxymethoxyphenacyl motif as potent HIV-1 reverse transcriptase inhibitors with improved solubility.Reductive Transformations of Carbonyl Compounds Catalyzed by Rhodium Supported on a Carbon Matrix by using Carbon Monoxide as a Deoxygenative Agent
P2860
Q27675380-2834ED8E-939F-4035-885E-EE8B7B6F9630Q27679282-934D4A56-B678-4C76-AFDB-9B577B09B6A1Q33860320-0AAF2844-9375-4505-A490-4DCD4C2B29C5Q34062476-9FB6AC8D-56C1-4C04-8006-A58CF70431C1Q36011620-3EF7F2E8-2F75-40F2-988B-C9644A12501CQ36306231-7AA153DB-83B9-4A19-9D1E-35085E625302Q37036648-CA7974CD-9043-4D61-97AC-3578B91CD4DEQ37164102-40932D29-FC30-4CDE-A9CD-5D96D9FE61BBQ37550710-1531F228-630C-44C1-A4C1-27A711AC3E77Q37697442-58044C53-49AB-472D-BDB1-0887C1084723Q38260066-02E3C437-2BCF-4873-A42E-6D19F5777F39Q38631098-D7777705-1140-4B41-B30C-6525ACFDBF50Q38669601-20F0A3A3-1F6B-431B-A1EC-119D265FB884Q39002274-9A6C4A37-5AB4-4280-B111-EB53495950D0Q40218320-50456D8C-34BB-43E8-977E-A48AEEDEE812Q41534943-84247C4F-B2FD-48A0-A6C5-975CFF9D5118Q41880104-10029ECD-C242-4FB7-811B-E09D5A664230Q42190198-F5A3046A-55BB-4C1E-ABF6-E79342C86ECAQ47446122-315FBD33-4B4F-4E4E-AFB5-E80471C06A8FQ57998768-F31BF56F-D158-425B-87D3-D7C4F82B6364
P2860
Design, synthesis, and preclinical evaluations of novel 4-substituted 1,5-diarylanilines as potent HIV-1 non-nucleoside reverse transcriptase inhibitor (NNRTI) drug candidates.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Design, synthesis, and preclin ...... bitor (NNRTI) drug candidates.
@ast
Design, synthesis, and preclin ...... bitor (NNRTI) drug candidates.
@en
type
label
Design, synthesis, and preclin ...... bitor (NNRTI) drug candidates.
@ast
Design, synthesis, and preclin ...... bitor (NNRTI) drug candidates.
@en
prefLabel
Design, synthesis, and preclin ...... bitor (NNRTI) drug candidates.
@ast
Design, synthesis, and preclin ...... bitor (NNRTI) drug candidates.
@en
P2093
P2860
P356
P1476
Design, synthesis, and preclin ...... ibitor (NNRTI) drug candidates
@en
P2093
Bingjie Qin
Chin Ho Chen
Keduo Qian
Kuo-Hsiung Lee
Lian-Qi Sun
P2860
P304
P356
10.1021/JM3007678
P407
P50
P577
2012-08-10T00:00:00Z